Last reviewed · How we verify
LEO 27847
At a glance
| Generic name | LEO 27847 |
|---|---|
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- LEO 27847 - A Study in Healthy Male Subjects (PHASE1)
- LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients (PHASE1)
- The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847 (PHASE1)
- LEO 27847 - Single Dose Bioavailability Study of Oral Solution Versus Tablet in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEO 27847 CI brief — competitive landscape report
- LEO 27847 updates RSS · CI watch RSS
- LEO Pharma portfolio CI